Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › insulin glargine/lixisenatide

insulin glargine/lixisenatide

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of insulin glargine/lixisenatide

2 trials tracked of insulin glargine/lixisenatide: 2 in phase 3 or 4.

2Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1
  1. Phase 4 Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus Completed
  2. Phase 3 iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4%
Nutrition & Obesity Medicine Sys. Review
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4% Comparing Combination Diabetes Drugs for Blood Sugar Control
This network meta-analysis evaluated 12,815 patients with type 2 diabetes to compare fixed-ratio combination products and their individual c…
A review of 12,815 patients found that insulin degludec/liraglutide may be best for lowering blood sugar, but has more side effects than oth…
Jun 4, 2026